Clinical Trial COGACNS0831


Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years.

Principal Investigator(s)

Adam Esbenshade


  • Protocol No. COGACNS0831
  • Open Date: 05/12/2011
  • Staging: Phase III
  • Age Group: Both Child and Adult
  • Scope: National
  • Objective: To determine the event free survival (EFS) and overall survival (OS) of children with completely resected ependymoma treated with post-operative conformal radiation therapy (cRT) and then randomized to receive or not receive four cycles of post radiation maintenance chemotherapy with vincristine, cisplatin, etoposide and cyclophosphamide (VCEC).
  • Disease Sites: Head/Neck; Neuro-Oncology; Pediatrics
  • Therapies: Chemotherapy - cytotoxic; Radiotherapy
  • Drugs: None Specified
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01096368
  • Secondary Protocol No: ACNS0831



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.